Pharmaceuticals Hong Kong

Hong Kong Multiple Sclerosis Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Hong Kong Multiple Sclerosis Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Hong Kong · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $38.2 Mn Placeholder estimate
Estimate 2025 $39.6 Mn 0.1% of the global market
Projected 2034 $55.5 Mn 39.9% Adds $15.8 Mn over 9 forecast years
CAGR 2025–2034 3.8% Faster than 1% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Hong Kong is 0.15% of the global market.
  • In APAC, the largest is China at $2.57 Bn.
  • Fastest growing: India at 5.7% a year.
  • Hong Kong ranks 8th of 10 by size in APAC.

Market size projection

Hong Kong

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$15.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Multiple Sclerosis Drugs Market market size by year, Hong Kong
YearMarket sizeChange that yearSince 2025
2024 (estimate) $38.2 Mn — —
2025 (base) $39.6 Mn +$1.5 Mn —
2026 (forecast) $41.2 Mn +$1.5 Mn +3.8%
2027 (forecast) $42.7 Mn +$1.6 Mn +7.7%
2028 (forecast) $44.3 Mn +$1.6 Mn +11.8%
2029 (forecast) $46.0 Mn +$1.7 Mn +16.1%
2030 (forecast) $47.8 Mn +$1.7 Mn +20.5%
2031 (forecast) $49.6 Mn +$1.8 Mn +25.1%
2032 (forecast) $51.5 Mn +$1.9 Mn +29.8%
2033 (forecast) $53.4 Mn +$2.0 Mn +34.8%
2034 (forecast) $55.5 Mn +$2.0 Mn +39.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Hong Kong Multiple Sclerosis Drugs Market Analysis at a glance
Market size, 2025$39.6 Mn placeholder estimate
Forecast, 2034$55.5 Mn placeholder estimate
Growth (CAGR), 2025–20343.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersRoche, Novartis AG, Biogen Inc, Sanofi, Merck KGaA and 1 more (see all)
Regulator in Hong KongDrug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026.
Active clinical trials6 in Hong KongSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Hong Kong Multiple Sclerosis Drugs Market Analysis Executive Summary

Multiple sclerosis drugs reduce relapses and slow disability in this immune disease of the brain and spinal cord.

Key segments of the multiple Sclerosis Drugs market include drug class (Anti-CD20 Antibodies, S1P Modulators and Interferons) and route (Infusion, Injectable and Oral).

Bar chart: Hong Kong Multiple Sclerosis Drugs market size, 2024–2034, placeholder estimates. $38.2 Mn in 2024, $39.6 Mn in 2025 and $55.5 Mn in 2034, 3.8% CAGR.
Hong Kong Multiple Sclerosis Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Hong Kong Multiple Sclerosis Drugs Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the multiple Sclerosis Drugs market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the multiple Sclerosis Drugs market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the multiple Sclerosis Drugs market.

Competitive Landscape for Multiple Sclerosis Drugs Market in Hong Kong

The multiple Sclerosis Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Multiple Sclerosis Drugs Market in Hong Kong

Multiple Sclerosis Drugs in Hong Kong: rules, payment and research

Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2] ClinicalTrials.gov lists 6 studies on Multiple Sclerosis Drugs that are recruiting, active or about to start in Hong Kong.⁠[3]

[1] Drug Office, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for multiple Sclerosis Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Hong Kong.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Multiple Sclerosis Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Multiple Sclerosis Drugs in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 16 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Multiple Sclerosis Drugs market in Hong Kong?
Placeholder estimate: about $39.6 Mn in 2025, rising to about $55.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Multiple Sclerosis Drugs market in Hong Kong growing?
Placeholder estimate: about 3.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Multiple Sclerosis Drugs market report cover?
The report splits the market by drug class (Anti-CD20 Antibodies, S1P Modulators, Interferons, BTK Inhibitors and more), route (Infusion, Injectable, Oral) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Multiple Sclerosis Drugs market?
Key players include Roche, Novartis AG, Biogen Inc, Sanofi, Merck KGaA and TG Therapeutics.
What is driving the Multiple Sclerosis Drugs market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the multiple Sclerosis Drugs market.
Who regulates Multiple Sclerosis Drugs in Hong Kong?
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health. Source: Drug Office, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
How many clinical trials on Multiple Sclerosis Drugs are running in Hong Kong?
6 studies are recruiting, active or about to start in Hong Kong, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.
How much research is published on Multiple Sclerosis Drugs?
PubMed lists 15 papers on Multiple Sclerosis Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Hong Kong

See all

Related on autoimmune diseases and brain and nerves

See the topic